T3D Therapeutics announced it has been awarded a competitive $50,000 Company Inception Loan (CIL) from the North Carolina Biotechnology Center. The CIL Program is designed to help bridge the early-stage funding gap that many North Carolina biotechnology companies face. Through the CIL program, loans of up to $50,000 are available for biotechnology companies in North Carolina. This program supports non-scientific business inception and related activities that are critical to the early-stage start-up of a biotechnology company.
Recent Posts
- A Novel Way to Reduce Alzheimer’s Amyloid Plaque Burden, Phase 2 Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at AAIC.
- Leading Alzheimer’s Expert Joins T3D Therapeutics’ Scientific Advisory Board
- T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program